147 related articles for article (PubMed ID: 34722213)
1. Dosage variability of veterinary drug products, containing furosemide, linked to tablet splitting.
Maggi L; Friuli V; Perugini P; Musitelli G; Venco L
Open Vet J; 2021; 11(3):471-482. PubMed ID: 34722213
[TBL] [Abstract][Full Text] [Related]
2. Dose Uniformity of Scored and Unscored Tablets: Application of the FDA Tablet Scoring Guidance for Industry.
Ciavarella AB; Khan MA; Gupta A; Faustino PJ
PDA J Pharm Sci Technol; 2016 11/12; 70(6):523-532. PubMed ID: 27974592
[TBL] [Abstract][Full Text] [Related]
3. Assessment of pharmaceutical quality of furosemide tablets from multinational markets.
Qureshi SA; McGilveray IJ
Drug Dev Ind Pharm; 1998 Nov; 24(11):995-1005. PubMed ID: 9876554
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and diuretic effect of furosemide after single intravenous, oral tablet, and newly developed oral disintegrating film administration in healthy beagle dogs.
Koh SK; Jeong JW; Choi SI; Kim RM; Koo TS; Cho KH; Seo KW
BMC Vet Res; 2021 Sep; 17(1):295. PubMed ID: 34488750
[TBL] [Abstract][Full Text] [Related]
5. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study.
McNamara PJ; Foster TS; Digenis GA; Patel RB; Craig WA; Welling PG; Rapaka RS; Prasad VK; Shah VP
Pharm Res; 1987 Apr; 4(2):150-3. PubMed ID: 3509139
[TBL] [Abstract][Full Text] [Related]
6. Tablet splitting: is it worthwhile? Analysis of drug content and weight uniformity for half tablets of 16 commonly used medications in the outpatient setting.
Helmy SA
J Manag Care Spec Pharm; 2015 Jan; 21(1):76-86. PubMed ID: 25562775
[TBL] [Abstract][Full Text] [Related]
7. Analysis of weight uniformity, content uniformity and 30-day stability in halves and quarters of routinely prescribed cardiovascular medications.
Margiocco ML; Warren J; Borgarelli M; Kukanich B
J Vet Cardiol; 2009 Jun; 11(1):31-9. PubMed ID: 19477704
[TBL] [Abstract][Full Text] [Related]
8. Utilization of a Single Experimental Design for the Optimization of Furosemide Modified-Release Tablet Formulations.
Vlachou M; Siamidi A; Dotsikas Y
Curr Drug Deliv; 2019; 16(10):931-939. PubMed ID: 31663479
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Discrepancy between the European Pharmacopoeia Test and an Adopted United States Pharmacopoeia Test Regarding the Weight Uniformity of Scored Tablet Halves: Is Harmonization Required?
Zaid AN; Ghoush AA; Al-Ramahi R; Are'r M
PDA J Pharm Sci Technol; 2012; 66(1):20-7. PubMed ID: 22307659
[TBL] [Abstract][Full Text] [Related]
10. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men.
Waller ES; Crismon ML; Smith RV; Bauza MT; Doluisio JT
Biopharm Drug Dispos; 1988; 9(2):211-8. PubMed ID: 3370308
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of seven furosemide tablets in man.
Straughn AB; Wood GC; Raghow G; Meyer MC
Biopharm Drug Dispos; 1986; 7(2):113-20. PubMed ID: 3708119
[TBL] [Abstract][Full Text] [Related]
12. Weight uniformity of split tablets required by a Veterans Affairs policy.
Polli JE; Kim S; Martin BR
J Manag Care Pharm; 2003; 9(5):401-7. PubMed ID: 14613437
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients.
Uchino K; Isozaki S; Amano J; Tanaka N; Saitoh Y; Nakagawa F; Tamura Z; Oka H
J Pharmacobiodyn; 1983 Sep; 6(9):684-91. PubMed ID: 6655548
[TBL] [Abstract][Full Text] [Related]
14. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
Rasool BK; Fahmy SA; Galeel OW
Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
[TBL] [Abstract][Full Text] [Related]
15. Prolonged-release hydroxypropyl methylcellulose matrix tablets of furosemide for administration to dogs.
Smal J; Marvola M; Liljequist C; Happonen I
J Vet Pharmacol Ther; 1996 Dec; 19(6):482-7. PubMed ID: 8971678
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Certain Pharmaceutical Quality Attributes of Lisinopril Split Tablets.
Fahelelbom KM; Al-Tabakha MM; Eissa NA; Javadi J
Sci Pharm; 2016 Oct; 84(4):646-653. PubMed ID: 27727195
[TBL] [Abstract][Full Text] [Related]
17. Compliance of scored tablet halves produced by Palestinian Pharmaceutical Companies with the new European Pharmacopoeia requirements.
Zaid AN; Ghosh AA
Arch Pharm Res; 2011 Jul; 34(7):1183-9. PubMed ID: 21811926
[TBL] [Abstract][Full Text] [Related]
18. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
Otsuka K; Wagner C; Selen A; Dressman J
J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
[TBL] [Abstract][Full Text] [Related]
19. Veterinary Products Committee working group report on feline and canine vaccination.
Gaskell RM; Gettinby G; Graham SJ; Skilton D
Vet Rec; 2002 Feb; 150(5):126-34. PubMed ID: 11871665
[TBL] [Abstract][Full Text] [Related]
20. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
Freerks L; Sommerfeldt J; Löper PC; Klein S
Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
